Literature DB >> 17478603

Doping dose of salbutamol and exercise training: impact on the skeleton of ovariectomized rats.

N Bonnet1, N Laroche, H Beaupied, L Vico, E Dolleans, C L Benhamou, D Courteix.   

Abstract

Previous studies in healthy rats have demonstrated a deleterious bone impact of beta-agonist treatment. The purpose of this study was to examine the trabecular and cortical effects of beta(2)-agonists at doping dose on treadmill exercising rats with estrogen deficiency. Adult female rats were ovariectomized (OVX; n = 44) or sham operated (n = 12). Then, OVX rats received a subcutaneous injection of salbutamol (SAB) or vehicle with (EXE) or without treadmill exercise for 10 wk. Bone mineral density (BMD) was analyzed by densitometry. Microcomputed tomography and histomorphometric analysis were performed to study trabecular bone structure and bone cell activities. After 10 wk, SAB rats presented a much more marked decrease of BMD and trabecular parameters. Exercise did not change the high level of bone resorption in OVX EXE SAB compared with OVX SAB group (both on COOH-terminal collagen cross-links and osteoclast number). These results confirm the deleterious effect of beta(2)-agonists on bone quantity (femoral BMD gain: OVX EXE, +6.8%, vs. OVX EXE SAB, -1.8%; P < 0.01) and quality (-8.0% of femoral trabecular thickness in OVX EXE SAB vs. OVX EXE), indicating that SAB suppresses the effect of EXE in OVX rats. Furthermore, we notice that the slight beneficial effect of exercise was mainly localized in the tibia. These findings indicate the presence of a bone alteration threshold below which there is no more alteration in structural bone quantity and quality. The negative effects of SAB on bone observed in this study in trained rats may indicate potential complications in doping female athletes with exercise-induced amenorrhea.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17478603     DOI: 10.1152/japplphysiol.01319.2006

Source DB:  PubMed          Journal:  J Appl Physiol (1985)        ISSN: 0161-7567


  7 in total

1.  Acute supra-therapeutic oral terbutaline administration has no ergogenic effect in non-asthmatic athletes.

Authors:  Anthony M J Sanchez; Fabio Borrani; Marie Amélie Le Fur; Anais Le Mieux; Virgile Lecoultre; Guillaume Py; Christophe Gernigon; Katia Collomp; Robin Candau
Journal:  Eur J Appl Physiol       Date:  2012-07-06       Impact factor: 3.078

2.  β2-Adrenergic receptor signaling in osteoblasts contributes to the catabolic effect of glucocorticoids on bone.

Authors:  Yun Ma; Jeffry S Nyman; Huan Tao; Heather H Moss; Xiangli Yang; Florent Elefteriou
Journal:  Endocrinology       Date:  2011-01-25       Impact factor: 4.736

3.  Guidelines for Dual Energy X-Ray Absorptiometry Analysis of Trabecular Bone-Rich Regions in Mice: Improved Precision, Accuracy, and Sensitivity for Assessing Longitudinal Bone Changes.

Authors:  Jiayu Shi; Soonchul Lee; Michael Uyeda; Justine Tanjaya; Jong Kil Kim; Hsin Chuan Pan; Patricia Reese; Louis Stodieck; Andy Lin; Kang Ting; Jin Hee Kwak; Chia Soo
Journal:  Tissue Eng Part C Methods       Date:  2016-04-15       Impact factor: 3.056

4.  The matricellular protein periostin is required for sost inhibition and the anabolic response to mechanical loading and physical activity.

Authors:  Nicolas Bonnet; Kara N Standley; Estelle N Bianchi; Vincent Stadelmann; Michelangelo Foti; Simon J Conway; Serge L Ferrari
Journal:  J Biol Chem       Date:  2009-12-18       Impact factor: 5.157

Review 5.  The Role of Nerves in Skeletal Development, Adaptation, and Aging.

Authors:  Ryan E Tomlinson; Blaine A Christiansen; Adrienne A Giannone; Damian C Genetos
Journal:  Front Endocrinol (Lausanne)       Date:  2020-09-23       Impact factor: 5.555

6.  The Potential Role of Exercise Training and Mechanical Loading on Bone-Associated Skeletal Nerves.

Authors:  Stefano Negri; T Jake Samuel; Seungyong Lee
Journal:  J Bone Metab       Date:  2021-11-30

7.  Beta-1 adrenergic agonist treatment mitigates negative changes in cancellous bone microarchitecture and inhibits osteocyte apoptosis during disuse.

Authors:  Joshua M Swift; Sibyl N Swift; Matthew R Allen; Susan A Bloomfield
Journal:  PLoS One       Date:  2014-09-11       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.